コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ody (ANCA)-associated vasculitis (AAV), with rapidly progressive glomerulonephritis.
2 ntigens (ANCA) is the most frequent cause of rapidly progressive glomerulonephritis.
3 more frequently recognized in the setting of rapidly progressive glomerulonephritis.
4 pic haematuria and stable kidney function to rapidly progressive glomerulonephritis.
5 utrophil accumulation in post-infectious and rapidly progressive glomerulonephritis.
6 re cases presenting as nephrotic syndrome or rapidly progressive glomerulonephritis.
7 as a potential novel therapeutic strategy in rapidly progressive glomerulonephritis.
8 ransplant nephritis alloantibodies mediating rapidly progressive glomerulonephritis.
9 xchange in patients with AAV or pauci-immune rapidly progressive glomerulonephritis and at least 12 m
10 iated vasculitis is the most common cause of rapidly progressive glomerulonephritis and immune-mediat
11 the use of PLEX to rescue organ function in rapidly progressive glomerulonephritis and lung haemorrh
12 basement membrane (GBM) disease present with rapidly progressive glomerulonephritis, and more than ha
13 as nephrotic syndrome, acute kidney injury, rapidly progressive glomerulonephritis, and pregnancy in
14 merular basement membrane (GBM) disease is a rapidly progressive glomerulonephritis (GN) resulting fr
16 e focal segmental glomerulosclerosis (FSGS), rapidly progressive glomerulonephritis/idiopathic cresce
18 Rapidly progressing AVCD is analogous to rapidly progressive glomerulonephritis in that inner ear
20 tation with full blown nephritic syndrome or rapidly progressive glomerulonephritis is uncommon and i
21 ciated vasculitis (AAV) is a common cause of rapidly progressive glomerulonephritis resulting in end-
23 ococcal glomerulonephritis, IgA nephropathy, rapidly progressive glomerulonephritis (RPGN), and membr
24 e as a potential therapeutic intervention in rapidly progressive glomerulonephritis, we treated mice